

Sun Pharmaceutical Industries Limited
SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com



27 May 2022

National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001

Scrip Symbol: SUNPHARMA

Scrip Code: 524715

Sub: Press Release

Dear Sir / Madam,

Please find enclosed herewith our Press Release relating to acquisition of Ureactiv™ Portfolio from Fiterman Pharma in Romania, which we shall be releasing after sending this letter to you.

This is for your information and dissemination.

Thanking you,

Yours faithfully,

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)
Company Secretary and Compliance Officer

Enclosed: As above



FOR IMMEDIATE RELEASE

Sun Pharma Acquires Uractiv™ Portfolio from Fiterman Pharma in Romania

Mumbai, India, May 27, 2022: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" including its subsidiaries and/or associate companies), today announced that one of its subsidiaries, S.C. Terapia S.A., Romania has acquired the Uractiv™ portfolio from Fiterman Pharma in Romania. The Uractiv™ portfolio comprises food supplements including minerals, vitamins and adjuvants; cosmetics and medical devices used for maintaining urinary tract health.

Uractiv™ is the No. 1 brand in its category in Romania, trusted by consumers for more than 10 years. The portfolio including 12 SKUs has annualised revenues of approximately US\$ 8.7 million*. The products cater to both adults and children.

"We are excited to add Uractiv™ to our consumer healthcare portfolio in Romania. This acquisition is in line with our strategy to further expand our non-prescription product basket in Romania and neighbouring markets," said Aalok Shanghvi, EVP & Head- Generic R&D, Generic Global BD and Emerging Markets, Sun Pharma. "We have a strong presence in Romania with Terapia being the number one company in the generics and OTC market*. We will leverage our robust marketing and distribution strengths to grow these brands further," he added.

The acquisition is subject to customary closing conditions and necessary regulatory approvals. Financial terms of the transaction are confidential.

*MAT Feb 2022 Cegedim

TM - All brand names and trademarks are the property of their respective owners.

Disclaimer:

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

Sun Pharmaceutical Industries Limited
SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com



About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050)

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across six continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6% of annual revenues in R&D. For further information, please visit www.sunpharma.com and follow us on Twitter @SunPharma_Live.

Contacts:

Investors:

Nimish Desai
Tel +91 22 4324 4324, Xtn 2778
Tel Direct +91 22 4324 2778

Mobile +91-98203 30182

E mail nimish.desai@sunpharma.com

Media:

Gaurav Chugh
Tel +91 22 4324 4324, Xtn 5373
Tel Direct +91 22 4324 5373

Mobile +91 98104 71414

E mail gaurav.chugh@sunpharma.com